Skip to main content Skip to main content
Introduction Video: Integrative Psychiatry Institute

The Future of Psychiatry

As we face unprecedented cases of depression and anxiety worldwide psychiatric providers are having to ask difficult questions about why our current pharmacological interventions aren’t solving the problem. In The Future of Psychiatry, you’ll get answers from two thought leaders…
Ana Cristina Ochoa
December 2, 2020

Introduction to Root Causes – HPA Axis

Chronic stress and HPA axis dysregulation are often present in mental health disorders but are commonly overlooked. Conventional ways of diagnosing cortisol irregularities simply fall short when assessing adrenal insufficiency. There is a wide range of adrenal function between the…
Ana Cristina Ochoa
December 2, 2020

Assessment and Treatment Planning

Providers who are beginning to adopt an integrative approach often ask, “Where do I start?” This course will show you the algorithm of exactly what to do first, second and third from the perspective of an integrative treatment plan. In…
Ana Cristina Ochoa
December 2, 2020

Emerging Frameworks in Psychiatry

Psychiatry is overdue for a fresh look at the conditions we diagnose and the treatments we provide. Scott Shannon, MD, a pioneer in the field of integrative psychiatry, reviews emerging frameworks from systems theory to game theory, and cutting-edge technologies…
Ana Cristina Ochoa
December 1, 2020

Frederick Barrett is a cognitive neuroscientist with training in behavioral pharmacology, and the Associate Director of the Johns Hopkins Center for Psychedelic and Consciousness Research. Dr. Barrett has been conducting psychedelic research at Johns Hopkins University since 2013, and his research in healthy participants and in patients with mood and substance use disorders focuses on the psychological and neurological mechanisms underlying the enduring therapeutic and other effects of psychedelic drugs. In 2017, he received an NIH “R03” grant as Principal Investigator to investigate biological mechanisms of psilocybin effects, the first federally funded research since the 1970s administering a classic psychedelic to people with psychedelic effects as the primary focus. He has developed measures of subjective effects of psychedelic drugs, and has also published first-in-human studies characterizing the acute and enduring effects of psilocybin on the brain. He is currently leading clinical trials to investigate the use of psilocybin to treat patients with major depressive disorder and co-occurring alcohol use disorder, and he is leading a number of ongoing studies aimed at better understanding the psychological, biological, and neural mechanisms underlying therapeutic efficacy of psychedelic drugs.

Will Van Derveer, MD is co-founder of Integrative Psychiatry Institute (IPI), along with friend and colleague Keith Kurlander, MA. He co-created IPI as an expression of what he stands for. First, that anyone can heal, and second that we medical providers must embrace our own healing journeys in order to fully command our potency as healers.

Dr. Van Derveer spent the last 20 years innovating and testing a comprehensive approach to addressing psychiatric challenges which transcends the conventional model he learned in medical school at Vanderbilt University and residency at University of Colorado, while deeply engaging his own healing path.

He founded the Integrative Psychiatric Healing Center in in 2001 in Boulder, CO, where he currently practices. Dr. Van Derveer regards unresolved emotional trauma as the most significant root cause of psychiatric symptoms in integrative psychiatry practice, along with gut issues, hormone imbalances, inflammation, mitochondrial dysfunction, and other functional medicine challenges. He is trained in Somatic Experiencing, EMDR, Internal Family Systems, and other psychotherapy techniques. His current clinical passion is psychedelic-assisted psychotherapy, which he mentors interested doctors in providing. An avid meditator, he has been a meditation instructor since 2004.

For the past several years Dr. Van Derveer has taught psychiatrists and other psychiatric providers integrative psychiatry in a number of settings, including course directing the CU psychiatry residents’ course as well as with Scott Shannon and Janet Settle at the Psychiatry MasterClass. In addition to his clinical work and teaching, he was co-investigator in 2016 a Phase II randomized clinical trial, sponsored by the Multidisciplinary Association for Psychedelic Studies (MAPS). He continues to support this protocol, now in a Phase III clinical trial under break-through designation by FDA.

Dr. Van Derveer is a diplomate of the American Board of Integrative and Holistic Medicine (ABoIHM) since 2013, and he was board certified in the first wave of diplomates of the new American Board of Integrative Medicine (ABIM) in 2016.